Cell based cancer vaccines
DCprime has both the infrastructure and capabilities to bring cancer immunotherapeutics to clinic. Initially exploiting the proprietary DCOne® platform, DCprime is developing cell based vaccines against different types of cancer.
Immuno-oncology beyond T cells
Since successful vaccination requires an immune system capable of mounting an effective response to the vaccine, DCprime continues to invest in research into furthering understanding of the condition of the immune system during or after treatment of cancer.
- Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy 26 July, 2018 Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy. Leiden, The Netherlands, 26 July 2018 – DCprime announces that the results of the phase I study with its lead product DCP-001 in AML have been published in Cancer Immunology, Immunotherapy. The phase I study was ... Read more
- DCprime and Glycotope announce licensing agreement and collaboration 18 July, 2018 DCprime and Glycotope announce licensing agreement and collaboration Leiden, The Netherlands, and Berlin, Germany, 18 July 2018 – DCprime bv, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have entered into a license agreement and research collaboration. Under ... Read more
- DCprime announces that Erik Manting PhD will join the company as its CEO 1 March, 2018 Leiden, The Netherlands, March 01, 2018 – DCprime announces today that Erik Manting PhD will become DCprime’s new Chief Executive Officer with immediate effect. Dr Manting succeeds Ada Kruisbeek, who will remain committed to DCprime as Chief Scientific Officer. Prior to joining DCprime, Erik spent 15 years in different management and commercial roles, of which ... Read more